Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD /

• Corporate Author: SpringerLink (Online service)
• Other Authors: Trifilieff, Alexandre (Editor)
• Format: Electronic eBook
• Language: English
• Published: Basel : Springer Basel : Imprint: Springer, 2014.
• Series: Milestones in Drug Therapy,
• Subjects: Medicine.; Pharmacology.; Respiratory organs > Diseases.; Biomedicine.; Pharmacology/Toxicology.; Pneumology/Respiratory System.

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are availabl...

Table of Contents:

• Current Pharmacotherapy for COPD
• The preclinical pharmacology of indacaterol
• The design of the indacaterol molecule
• The early clinical development of Indacaterol
• INHANCE: An adaptive confirmatory study with dose selection at interim
• Phase III clinical efficacy studies – lung function
• Phase III Clinical Efficacy of Indacaterol
• Patient-centered Outcomes
• The history and performance of the Breezhaler device
• What does the future hold for the therapy of COPD?  .